NCT00048607已完成3 期
A Double-Blind, Multicenter, Placebo and Active-Controlled, Acute Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 600
- 主要终点
- HAMD-17 total score at week 8. Tolerability.
研究概览
简要总结
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression
详细描述
The duration of treatment is 8 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
HAMD-17 total score at week 8. Tolerability.
时间窗: at week 8
次要结局
- CGI-I Scale score at week 8 and Sheehan Disability Scale at week 8(at week 8)
研究者
相似试验
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)Major Depressive DisorderNCT00035009Merck Sharp & Dohme LLC468
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)Major Depressive DisorderNCT00042029Merck Sharp & Dohme LLC324
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)Major Depressive DisorderNCT00034944Merck Sharp & Dohme LLC495
已完成
3 期
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)Depressive Disorder, MajorNCT02709655H. Lundbeck A/S683
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)Major Depressive DisorderNCT00035295Merck Sharp & Dohme LLC584